Yu AF, et al. - A single-center retrospective cohort study was planned to determine the cardiac safety of trastuzumab without anthracyclines outside of a clinical trial setting. Findings revealed an overall low incidence of symptomatic heart failure and asymptomatic left ventricular ejection fraction (LVEF) decline among patients receiving trastuzumab without anthracyclines. Based on the findings, researchers suggested less intensive cardiac monitoring as appropriate during trastuzumab therapy without anthracyclines.